Amgen, Global Development Leader, Bone Therapeutic Area
Endocrinology
Dr. Rachel B. Wagman, MD
|
|
Give Review
Rachel Wagman is an expert in the field of Endocrinology. He attended Jefferson Medical College. Dr. Rachel B. Wagman is a published MD. He has 21 publications published. The most current publication "Fracture incidence in a large cohort of men age 30years and older with osteoporosis."
Publications
- Fracture incidence in a large cohort of men age 30 years and older with osteoporosis.
- Effects of up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension.
- Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who rem...
- The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension.
- Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia(®) (denosumab) for the treatment of postmenopausal osteoporosis.
- Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial.
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial.
- The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
- Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off-treatment biopsy study.
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
- Comparison of the Effect of Denosumab and Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Ra...
- Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded...
- Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
- Beyond bone mineral density-navigating the laboratory assessment of patients with osteoporosis.
- Identifying fracture risk in postmenopausal women.
- Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
- Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass.
- Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis.
- Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study.
- Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.
Schools
Thomas Jefferson University
Thomas Jefferson University Hospital
Stanford University School Med
Conditions Treated
- Hyperlipidemia
Doctors Specialties
- Endocrinology
Accepted Insurances
- Blue Card PPO
- Individual and Family PPO
Education
-
Stanford University -
Thomas Jefferson University -
Jefferson Medical College
Helpful Reviews
Similar Doctors
|
Dr. Gulnar Poorsattar, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Yaroslav Gofnung, MD
This Doctor is OpenDoctor Recommended.
|